How Big Is the Hypoparathyroidism Market | Forecast & Insights 2026

Q: What is the market size of the hypoparathyroidism market?

It was valued at USD 0.68 Billion in 2024 and is projected to reach USD 0.99 Billion by 2031.

Q: What is the CAGR of the hypoparathyroidism market?

The hypoparathyroidism market is expected to grow at a CAGR of 5.60% from 2025 to 2031.

Q: What drives the hypoparathyroidism market?

Rising prevalence, growing awareness, and innovation in PTH therapy are driving the market.

Q: What are the main treatment options?

PTH replacement therapy, calcium and vitamin D supplementation, and experimental gene therapies.

Q: Which region dominates the hypoparathyroidism market?

North America dominates due to strong healthcare infrastructure and favorable regulatory support.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA6840

Publication Date: Jul 2025

How big is the Hypoparathyroidism Market?

According to 6Wresearch internal database and industry insights, the Global Hypoparathyroidism Market was valued at USD 0.68 Billion in 2025 and is projected to reach USD 0.99 Billion by 2032, growing at a compound annual growth rate (CAGR) of 5.60% during the forecast period of 2026–2032.

For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Global Hypoparathyroidism Market.

View Main Report Schedule Analyst Call

The market is driven by increased diagnosis rates, rising awareness of rare endocrine disorders, advancements in recombinant parathyroid hormone therapies, and growing research investments into orphan drugs.

Key Growth Drivers of the Hypoparathyroidism Market

Increasing awareness and diagnosis of endocrine disorders
Growing use of recombinant parathyroid hormone treatments
Favorable regulatory policies for orphan drug development
Rising prevalence of postsurgical hypoparathyroidism
Expansion of healthcare infrastructure and access in emerging economies

Hypoparathyroidism Market Trends

The hypoparathyroidism market is evolving with innovations in hormone replacement therapy. A key trend includes the development of long-acting parathyroid hormone analogs that reduce the frequency of dosing. The shift from conventional calcium and vitamin D supplementation to biologics and targeted hormone therapies is improving long-term patient outcomes. Digital health platforms are also enhancing disease tracking and patient management. Research into gene therapies is underway, aiming at offering curative options for chronic hypoparathyroidism.

Emerging Developments in the Hypoparathyroidism Market

A number of biotechnology companies are working on newer more sustained-release molecular therapies. Newer PTH analogs with fewer side effects are being tested as part of clinical trials. Biosimilars are being launched together, as pharma companies are working together with research institutions. Individualized medicine is under investigation to enable the patient specific genetic profile to develop a corresponding treatment. Greater product approvals and patient access programs, make the emerging markets to experience greater penetration.